ExLibris header image
SFX Logo
Title: Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression
Source:

Proceedings of the National Academy of Sciences of the United States of America [0027-8424] Pearse, R N yr:2001


Collapse list of basic services Basic
Full text
Full text available via PubMed Central
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Bezieau, S. "High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis." Human mutation 18.3 (2001): 212-24. Link to Full Text for this item Link to SFX for this item
2. Abe, M. "Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion." Blood 104.8 (2004): 2484-2491. Link to SFX for this item
3. Engel, E. "Alendronate and etidronate do not regulate interleukin 6 and 11 synthesis in normal human osteoblasts in culture." Calcified tissue international (2003): 228-35. Link to SFX for this item
4. Rahemtulla, A. "Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index." Blood 102.3 (2003): 1064-9. Link to SFX for this item
5. Abdeladhim, S. "Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial." Blood 111.4 (2008): 1805-10. Link to SFX for this item
6. Joy, PJ P. "Chromosomal and genetic abnormalities in myeloma." Clinical and laboratory haematology 24.5 (2002): 259-269. Link to Full Text for this item Link to SFX for this item
7. Nilsson, Susan K K. "Osteopontin: a bridge between bone and blood." British journal of haematology 134.5 (2006): 467-74. Link to Full Text for this item Link to SFX for this item
8. Webb, David N A. "Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells." Blood 106.4 (2005): 1232-9. Link to SFX for this item
9. Wai, Philip Y Y. "The role of Osteopontin in tumor metastasis." The Journal of surgical research 121.2 (2004): 228-41. Link to SFX for this item
10. Herv, M. "Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications." Journal of clinical oncology 29.14 (2011): 1893-1897. Link to SFX for this item
11. Cilloni, D. "From genes to therapy: The case of Philadelphia chromosome-positive leukemias." Annals of the New York Academy of Sciences 963 (2002): 306-312. Link to Full Text for this item Link to SFX for this item
12. Kennedy, N. "Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure." Journal of clinical oncology 27.11 (2009): 1788-93. Link to SFX for this item
13. Intini, D. "Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma." Hematological oncology 25.1 (2006): 6-10. Link to Full Text for this item Link to SFX for this item
14. Drach, J. "The biology of multiple myeloma." Journal of cancer research and clinical oncology 126.8 (2000): 441-447. Link to Full Text for this item Link to SFX for this item
15. Mellqvist UH, Ulf-Henrik H. "Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin,." Cancer 112.1 (2008): 129-35. Link to Full Text for this item Link to SFX for this item
16. Hsieh, Yu-Hua H. "Papilloma development is delayed in osteopontin-null mice: implicating an antiapoptosis role for osteopontin." Cancer research 66.14 (2006): 7119-7127. Link to SFX for this item
17. Du, R. "HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion." Cancer cell 13.3 (2008): 206-220. Link to SFX for this item
18. Stewart, A Keith K. "Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant." Clinical cancer research 10.24 (2004): 8170-6. Link to SFX for this item
19. Calvi, L M M. "Osteoblastic cells regulate the haematopoietic stem cell niche." Nature 425.6960 (2003): 841-846. Link to Full Text for this item Link to SFX for this item
20. Stier, S. "Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size." The Journal of experimental medicine 201.11 (2005): 1781-91. Link to Full Text for this item Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.